ArticleJAMA network open2024
Disparities in Continuous Glucose Monitoring Among Patients Receiving Care in Federally Qualified Health Centers.
Article in JAMA network open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07587151 (The Role of Remote Pharmacy Services With Continuous Glucose Monitoring in an Underserved Population), which is not on this map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Role of Remote Pharmacy Services With Continuous Glucose Monitoring in an Underserved Population
Who cites it
22 citing papers in PubMed.
- Management of type 2 diabetes, 2026. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Diabetologia · 2026Article
- Comparative Evaluation of Traditional and Emerging Glycemic Biomarkers in Diabetes.Current issues in molecular biology · 2026Review
- The Impact of an Experience-Based Versus Traditional Continuous Glucose Monitoring Curriculum on Internal Medicine Resident Confidence and Knowledge.Journal of general internal medicine · 2026Article
- Associations Between Sleep Quality and Continuous Glucose Monitoring-Derived Metrics in Individuals With Type 2 Diabetes.Journal of sleep research · 2026Article
- Beyond Coverage Expansion: Exploring Persistent Barriers to CGM Utilization in the Clinical Environment.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Article
- US race/ethnic disparities in diabetes technologies: a systematic review and meta-analysis of 950 000 individuals.Journal of the Endocrine Society · 2026Review
- Piloting a Postdischarge Virtual Glucose Monitoring Program for Patients With Diabetic Foot Wound in a Safety-Net Health System.Journal of diabetes science and technology · 2026Article
- Review
- Primary Care-Initiated Continuous Glucose Monitoring in Adults With Insulin-Treated Diabetes.JAMA network open · 2026Article
- Continuous Glucose Monitoring in Type 2 Diabetes: Clinical Outcomes, Disparities in Access, and Cost-effectiveness.Current diabetes reports · 2026Review
- Advances in diabetes technology: clinical implications, limitations, and future perspectives.Hormones (Athens, Greece) · 2026Review
- Article
- Barriers to use of continuous glucose monitoring among adults with type 2 diabetes.Diabetes research and clinical practice · 2026Article
- Characterizing Continuous Glucose Monitoring Prescription Patterns Between 2020 and 2024: A Retrospective Study at a Single Primary Care Facility in the United States.Journal of diabetes research · 2026Article
- Promoting Access to Continuous Glucose Monitoring among Patients with Type 2 Diabetes in Rural Areas: A Report from the Field.Journal of health care for the poor and underserved · 2026Article
- Navigating Continuous Glucose Monitoring Adoption: Insights From Hispanic Adults With Insulin-Treated Type 2 Diabetes.Journal of diabetes research · 2026Article
- What's New and Around the Corner in CGM?Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2025Article
- The role of continuous glucose monitoring (CGM) in psychiatric symptom management.CNS spectrums · 2025Review
- Exploring Combined Use of Continuous Glucose Monitoring and Anti-Diabetes Medications on Glycaemic Control for People With Type 2 Diabetes Not Using Insulin.Endocrinology, diabetes & metabolism · 2025 · on this mapObservational
- Enhancing Health Equity and Patient Engagement in Diabetes Care: Technology-Aided Continuous Glucose Monitoring Pilot Implementation Project.JMIR diabetes · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Importance: While continuous glucose monitoring (CGM) has been found to improve diabetes care processes and outcomes, adoption remains low. Objective: To examine the association between CGM prescriptions and individual characteristics among patients with type 1 or 2 diabetes (T1D and T2D, respectively). Design, Setting, and Participants: Retrospective cross-sectional study using electronic health record data for patients with T1D or T1D from 275 clinic sites nationwide between January 2014 and February 2021. All participating clinics were federally qualified health centers (FQHCs), the largest US system of primary care for vulnerable populations. Data were analyzed from September 2022 to August 2024. Main Outcomes and Measures: Sociodemographic factors, clinical characteristics, and CGM prescription orders. Results: A total of 1168 patients with T1D (mean [SD] age, 41.8 [16.0] years; 600 [51.4%] male; 372 [31.9%] Black; 262 [22.4%] Hispanic, and 750 [64.2%] White patients) and 35 216 patients with T2D (mean [SD] age, 58.4 [13.1] years; 19 772 [56.1%] female; 12 030 [34.2%] Black; 12 979 [36.9%] Hispanic, and 20 413 [58.0] White patients) were included. Overall, CGM prescriptions were infrequent (129 [11.0%] for patients with T1D and 362 [1.0%] for those with T2D) but increased throughout the study period. Among patients with T1D, those who reported Hispanic ethnicity (odds ratio [OR], 0.30; 95% CI, 0.16-0.57), Black race (OR, 0.61; 95% CI, 0.38-0.99), or were uninsured (OR, 0.42; 95% CI, 0.23-0.74) had lower multivariable odds of receiving a CGM prescription than White or insured adults, respectively. Similar findings were observed among patients with T2D reporting Hispanic ethnicity (OR, 0.43; 95% CI, 0.32-0.57), Black race (OR, 0.76; 95% CI, 0.59-0.98), or being uninsured (OR, 0.42; 95% CI, 0.31-0.58), relative to their counterparts. Among patients with T2D, hemoglobin A1c values higher than 9.0% (OR, 3.17; 95% CI, 2.37-4.21) and a greater burden of diabetes complications were associated with higher odds of CGM prescription. Conclusions and Relevance: In this cross-sectional study of electronic health record data, rates of CGM prescription orders were low among FQHC patients with T1D and T2D. Disparities in CGM orders were observed among patients reporting Hispanic ethnicity, Black race, and those who lacked health insurance. Future research is needed to understand the causes of infrequent CGM orders in FQHCs and drivers of observed disparities in this vulnerable patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.